European Psychiatry - Volume 41

S480

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S465–S520

EV0234

The Kynurenine pathway in

pancreatic carcinoma

C. Blesl

, A. Tmava

, A. Baranyi

, A. Meinitzer

, A. Painold

A. Holl

, V. Stadlbauer-Köllner

, H.P. Kapfhammer

, S. Mörkl

1 ,

∗

Medical university of Graz, psychiatry, Graz, Austria

Medical university of Graz, clinical institute of medical and

chemical laboratory diagnostics, Graz, Austria

Medical university of Graz, gastroenterology and hepatology, Graz,

Austria

∗

Corresponding author.

Introduction

Pancreatic carcinoma (PC) belongs to the most

aggressive tumours worldwide, with a five year survival of 7%.

Mostly, diagnosis is made in late stages, as by now no early detec-

tion method is available. Symptoms of depression occur frequently

before diagnosis of PC. PC and depression are both known to go

along with changes in the kynurenine-pathway.

Objectives

This study aimed to examine the kynurenine pathway

( Figure 1 )

and evaluate a possible depression in newly diagnosed

PC patients in comparison to healthy controls (HC).

Methods

26 PC patients and 26 age and sex matched HC partic-

ipated in this study. We investigated serum-levels of kynurenine,

kynurenic-acid, quinolinic-acid and tryptophan. To diagnose fea-

tures of depression SKID-II and BDI were used.

Results

None of the participants fulfilled criteria of a depres-

sive episode. Regarding BDI-scores, 2 PC-patients showed features

of mild depression. PC patients showed significantly lower

tryptophan-levels (

= 0.05) and significantly increased quinolinic-

acid levels (

= 0.01) compared to HC. Quinolinic-acid levels were

correlated with BDI (

= 0.23,

= 0.02).

Conclusions

Our study results imply IDO-activation and

kynurenine-pathway activation by showing decreased trypto-

phan and high quinolonic-acid levels in our PC patients compared

to HC. Larger studies are needed to gather further insight in the

kynurenine pathway in PC.

Figure 1

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2017.01.564

EV0235

The mortality gap. Patients with

serious mental conditions. Mortality,

morbidity and use of health services

L.H. Myklebust

1 ,

∗

, R. Wynn

Fagavdelingen, Nordlandssykehuset HF, Bodø, Norway

The Arctic university of Northern Norway- clinical medicine,

telemedicine and e-health, Tromsø, Norway

∗

Corresponding author.

Introduction

Mental illness are among the most prevalent causes

of death

[1] .

Larger population based studies are needed in order

to control the high mortality rates for psychiatric patients

[2] .

Objective

To examine the relationship between psychiatric dis-

ease and somatic illness.

Method

Data from health-related databases and registries are

cross-matched by social security number for all psychiatric patients

in North-Norway for 2008–2016/2017.

= 4000–6000.

( Table 1 )

Mortality is considered multifactorial, and risk factors may appear

as both direct and indirect causes. A high number of demographic,

somatic, psychiatric and service related variables allow the study

to control for interactions and confounding associations by multi-

variate analyses.

Results/planned papers

– 1 A case-register study of the comor-

bidity of mental and somatic disorders in North Norway: Research

protocol.

– 2 Increased mortality in psychiatric patients: A case-registry

study.